Update shared on08 Aug 2025
Fair value Increased 8.47%Sight Sciences' consensus price target has increased, primarily reflecting improved revenue growth forecasts, with fair value rising from $3.93 to $4.27.
What's in the News
- Raised full-year 2025 revenue guidance to $72–76 million (still a 5–10% decline vs. 2024), from previous $70–75 million.
- Cost-utility analysis found TearCare® saves $903 annually per patient compared to cyclosporine in treating moderate to severe meibomian gland disease, with superior cost-effectiveness and health utility.
- Published 24-month SAHARA RCT results show TearCare® delivers sustained, statistically significant improvements in dry eye disease signs and symptoms, with 66% of patients needing no additional treatment after two treatments.
Valuation Changes
Summary of Valuation Changes for Sight Sciences
- The Consensus Analyst Price Target has risen from $3.93 to $4.27.
- The Consensus Revenue Growth forecasts for Sight Sciences has significantly risen from 7.6% per annum to 8.5% per annum.
- The Future P/E for Sight Sciences has risen slightly from 23.03x to 24.10x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.